Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03896646
Other study ID # 2018-1008
Secondary ID NCI-2019-0158620
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 10, 2019
Est. completion date September 30, 2024

Study information

Verified date April 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial aims to improve hepatocellular carcinoma (HCC) tumor responses in patients undergoing Y90 radioembolization by using personalized dosimetry as part of treatment planning. Using standard calculations for Y90 doses may not be specific enough for individual patients given that there can be differences in how tumor cells and liver cells respond to radiation. Personalized dose plans may help improve treatment and outcomes in liver cancer.


Description:

PRIMARY OBJECTIVES: I. To achieve tumor objective response rates of 75% using voxel based dosimetry when the mean dose (Dmean) to tumor is targeted to be greater than 200 Gray (Gy). SECONDARY OBJECTIVES: I. Correlate changes in liver function and Common Terminology Criteria for Adverse Events (CTCAE) incidence to the mean absorbed dose to normal liver. II. Prospectively validate the accuracy of our published tumor dose response prediction based on the yttrium Y 90 glass microspheres (yttrium-90 [Y90]) tumor dose volume histograms (DVHs). III. Correlate predicted tumor doses macroaggregated albumin (MAA) scan with actual doses delivered (Y90 scan). IV. Develop a tumor dose response model prediction based on the MAA dose maps. V. Develop a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography/computed tomography hepatobiliary iminodiacetic acid (SPECT/CT HIDA) imaging. VI. Develop a model correlating the relative tumor to normal liver enhancement on CT imaging and Cone beam CT imaging to the uptake on SPECT CT Tc99m MAA imaging (gold standard). VII. Compare tumor and normal liver doses estimations from SPECT CT Bremsstrahlung imaging to positron emission tomography (PET) CT imaging. OUTLINE: Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization. After completion of study treatment, patients are followed up at 3 and 6 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 42
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients over 18 years of age, of any race or sex, who have unresectable hepatocellular carcinoma of the liver, and who are able or have a fully able legal guardian to give informed consent, will be eligible. Patients must have an ECOG Performance Status score of </=2, with a life expectancy of >/=3 months, and must be non-pregnant with an acceptable contraception in premenopausal women. Patients must be >4 weeks since prior radiation or prior surgery and at least one month post chemotherapy. 2. At least one lesion >/= 3.0 cm in shortest dimension 3. AST or ALT <5 times ULN 4. Bilirubin </= 2.0 mg/dL (unless segmental infusion is used) 5. Negative pregnancy test in premenopausal women Exclusion Criteria: 1. Contraindications to angiography and selective visceral catheterization 2. Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) to the lungs with a single injection, or greater than 50 Gy for multiple injections 3. Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels) 4. Significant extrahepatic disease representing an imminent life-threatening outcome 5. Severe liver dysfunction or pulmonary insufficiency 6. Active uncontrolled infection 7. Significant underlying medical or psychiatric illness 8. Pregnant 9. Pre-existing diarrhea/illness, co-morbid disease or condition that would preclude safe delivery of TheraSphere® treatment and place the patient at undue risk 10. Infiltrative tumors

Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
  • Stage IIIB Hepatocellular Carcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Hepatocellular Carcinoma AJCC v8
  • Unresectable Hepatocellular Carcinoma

Intervention

Procedure:
Computed Tomography
Undergo SPECT/CT HIDA scan
Other:
Hepatobiliary Iminodiacetic Acid Scan
Undergo SPECT/CT HIDA scan
Procedure:
Single Photon Emission Computed Tomography
Undergo SPECT/CT HIDA scan
Radiation:
Yttrium Y 90 Glass Microspheres
Undergo radioembolization with yttrium Y 90 glass microspheres
Procedure:
Yttrium-90 Microsphere Radioembolization
Undergo yttrium-90 microsphere radioembolization

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor objective response rate (ORR) Assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. The ORR of treated tumors will be determined. Will perform a cluster bootstrap in which patients (not tumors) are sampled with replacement. Will construct a 95% confidence interval using the 2.5% and 97.5% quantiles of the bootstrap sampling distribution. Up to 6 months
Secondary Changes in liver function Will analyze the correlation in changes in liver function to the mean absorbed dose to normal liver. The hepatobiliary iminodiacetic acid (HIDA) scan will be used to estimate the body-surface area corrected mebrofenin clearance rate in %-activity/sec/m^2 using published methodology. The change in liver function after radioembolization will be calculated and correlated to the radiation dose distribution to the normal liver. Will use Wilcoxon and two-sample t-tests to measure significance of association. Up to 6 months
Secondary Changes in Common Terminology Criteria for Adverse Events (CTCAE) incidence Will analyze the correlation in changes in CTCAE incidence to the mean absorbed dose to normal liver. Will create waterfall charts of CTCAE and mean absorbed normal liver in liver. Will use Wilcoxon and two-sample t-tests to measure significance of association and scatterplots and regression (linear or non-linear) to predict actual doses delivered from predicted tumor dose. Up to 6 months
Secondary Accuracy of published tumor dose response prediction based on the yttrium-90 (Y90) tumor dose volume histograms Lin's concordance correlation, t-test, and Bland-Altman analysis will be performed on pair-wise estimate of tumor doses. Develop tumor dose response curves using logistic regression and assess significance of parameters. Furthermore, we will compute the half-maximal dose (D50%), positive predictive value, negative predictive value and its 95% confidence interval from this prospective study. These values will be compared to those from the retrospective study for equivalence using the z-test. Up to 6 months
Secondary Prediction of tumor doses macroaggregated albumin (MAA) scan with actual doses delivered (Y90 scan) Lin's concordance correlation, t-test, and Bland-Altman analysis will be performed on pair-wise estimate of tumor doses. Will use scatterplots and regression (linear or non-linear) to predict actual doses delivered from predicted tumor dose. A correlation analysis of the predicted tumor doses from the MAA images with the actual tumor doses delivered from Y90 images will be performed. The linear-correlation coefficient will be computed. A Bland-Altman analysis will be performed to compute the bias and the 95% limits of agreement. Up to 6 months
Secondary Development of tumor dose response model prediction based on MAA dose maps Mean tumor doses based the planning 99mTc-MAA images will be computed using voxel dosimetry. A univariate logistic regression model will used to determine tumor dose metrics (D50%) that correlated with mRECIST-based tumor response at 3 and 6 months. Up to 6 months
Secondary Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging A regression analysis of the change in liver function from the pre- and post-procedural HIDA SPECT/CT scans (changes in %/min) as a function of the normal liver absorbed dose will be performed. Up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Completed NCT00988741 - Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy Phase 2
Recruiting NCT03942328 - Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Phase 1/Phase 2
Completed NCT01900002 - Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT06315101 - Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
Not yet recruiting NCT04947956 - Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
Completed NCT01004978 - Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Phase 3
Active, not recruiting NCT01217034 - Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib Phase 2
Terminated NCT03695250 - BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Phase 1/Phase 2
Completed NCT02006030 - Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma Phase 2
Recruiting NCT05135364 - HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure Phase 2
Recruiting NCT06117891 - An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Recruiting NCT05957640 - Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma Phase 1
Recruiting NCT04736121 - Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients N/A
Recruiting NCT05168163 - Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Phase 2
Withdrawn NCT03345225 - A Clinical Study of Precision TACE (P-TACE) With Surefire N/A
Recruiting NCT05667064 - Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT02989870 - Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Phase 1
Active, not recruiting NCT04829383 - A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma Phase 2